**MINUTES**

**CPIC CONFERENCE CALL**

DATE: June 7, 2012

PRESENT: Adriana Malheiro, Andrea Gaedigk, Deanna Kroetz, Ellie McDonagh, Jesse Swen, John Callaghan, Julie Johnson, Kathryn Teng, Kevin Hicks, Kristine Crews, Li Gong, Marc Williams, Mark Avigan, Mary Relling, Mary Rouse, Michelle Carrillo, Rachel Tyndale, Robert Freimuth, Steven Scherer, Stuart Scott, Todd Skaar, Uli Broeckel

| TOPIC | DISCUSSION/ACTION | FOLLOW-UP |
| --- | --- | --- |
| Introduction of the Coordinating Committee | A CPIC Coordinating Committee (Drs. Long, Klein, Relling, Johnson, and Roden) has been formed. | Its recommendations will be presented to CPIC. |
| Possible new gene/drug pairs | Several new gene/drug pairs have been brought up recently. None are currently being used or contemplated by CPIC members, but some may change status.  Efavirenz/CYP2B6: No advocates, but suggested to check with Dr. Desta at IU.  Tamoxifen/CYP2D6: Lots of chatter recently because of methodological problems with recent negative studies. Tamoxifen consortium still not concluding that testing is ready for clinical implementation.  Aminoglycosides/ototoxicity. Suggested by Bill Newman. Marc Williams mentioned that some states may be incorporating mitochondrial DNA variants into newborn screening for deafness—might be implications for future drug use if adopted. | Encourage CPIC members to be aware of these gene/drug pairs and to suggest new ones. Perhaps an additional survey of CPIC members is due.  Mary to follow up with Desta. |
| How to prioritize new gene/drug pairs? | Discussed that this process might be better formalized. Circles back to original CPIC goal of enumerating the characteristics of a gene/drug pair that makes them worthy of CPIC guidelines. | Can put on future agenda to discuss. Volunteers wishing to work on summarizing key characteristics of clinically important gene/drug pairs are (again) welcome to spearhead effort. |
| Disclaimer | Wording for this disclaimer was finalized over 1 year ago; this must be included in all CPIC guidelines. | Authors should check most recent versions of CPIC guideline template on CPIC members’ site |
| Look-up tables to be added to PharmGKB | Tables relating diplotypes to dosing recommendations and active decision supported alerts were displayed for CYP2D6, TPMT, which will be shared with PharmGKB to begin to discuss how to post. The TPP is working on look-up tables for CYP2C19. | Mary will submit 2D6 and TPMT tables to PharmGKB staff, who will work out processes to vet, update, version, and post. |
| Guidelines in progress | HLA/Phenytoin guideline: John Callaghan, Lisa Smith, Ming Ta, Michael Lee, Teri Klein, Michelle Carrillo are working on it. Question raised if information differs enough from CBZ guideline.  HLA CBZ guideline: Susan Leckband has; otherwise no report.  IL28B/interferon: draft in progress.  HLA/allopurinol: submitted  DYPD 5FU: maturing draft.  TCAs: report by Kevin Hicks; slowed down by 7 drugs and discussion of relative importance of PK data alone, but progress continues.  SSRIs: Susan Leckband has, no report | Mary will work with PharmGKB to check on possible merging and/or on updates of phenytoin/CBZ. |
| Updating existing guidelines | All guidelines must be reviewed at least every 2 years, and updated as data change. Two types of updates: minor update (change in supplementary material) and major (change in Table 2 of main manuscript). Rachel working with CPT to accommodate both types such that they will be indexed in PubMed. CPIC members strongly endorsed having all updated (and original) guidelines undergo thorough peer review and criticism via CPT. Updates will need to be submitted to CPT 2 yrs prior to original submission date.  Issue of versioning of guidelines was raised; all updates to PharmGKB should have clear identification as to “version”. | Rachel and Teri will assist in getting updates started. Approximate submission dates will be:  TPMT: October 2012  Clopidogrel: Dec 2012  Warfarin: April 2013  May need teleconference to clarify. |
| July and August meetings | Will be cancelled; may be phone calls for updates with Rachel (see below). |  |
| ASHP endorsement of CPIC clopidogrel guideline | ASHP’s endorsement of clopidogrel guidelines posted to CPIC members’ site. They plan to review in this order: 1.Abacavir, 2.Codeine, 3.Warfarin  4. Thiopurines --- and then keep up with new guidelines. ASHP needs “permanent” URL for guidelines to link to from their site. Discussed that all CPIC guidelines should have stable URL to allow linking from external sites. | PharmGKB staff to provide permanent link for clopidogrel to ASHP. |